老年骨髓增生异常综合征患者非清髓与减低强度异基因造血干细胞移植的比较
该回顾性研究分析了151例50岁以上接受非清髓(NMA)或减低强度(RIC)异基因造血干细胞移植的MDS或MDS/MPN患者,比较两种预处理方案的结局。全队列中两组复发累积发生率、非复发死亡率和总生存无显著差异,但NMA组移植物排斥和慢性GVHD发生率更高;在65岁以下患者中,NMA预处理与更高的NRM和更短OS趋势相关,且多因素分析中预处理方案仍是该亚组NRM和OS的预后因素。
要点
- 全队列中NMA与RIC预处理在复发、非复发死亡和总生存上无显著差异。
- NMA组移植物排斥和慢性GVHD发生率高于RIC组。
- 65岁以下患者中NMA预处理与更高NRM和更短OS趋势相关,RIC可能更获益。
核心结论
- 在MDS患者中NMA与RIC预处理可获得相似的疾病控制,但尤其65岁以下患者可能从RIC-HSCT中获益。
研究设计与样本
- 回顾性分析151例50岁以上接受NMA或RIC异基因造血干细胞移植的MDS或MDS/MPN患者,并按移植时年龄小于或大于65岁分别分析。
主要发现
- NMA组移植物排斥和慢性移植物抗宿主病发生率更高。
- 全队列中复发累积发生率、非复发死亡率和总生存按预处理方案比较无显著差异。
- 65岁以下患者中NMA预处理与更高非复发死亡率和更短总生存呈趋势相关,而复发累积发生率两组相似。
- 多因素分析中预处理方案仍是65岁以下患者非复发死亡率和总生存的预后因素。
临床怎么用
- 对于50岁以上MDS或MDS/MPN患者,NMA与RIC均可考虑,疾病控制相似。
- 65岁以下患者选择预处理方案时需权衡NMA相关更高NRM和更短OS的趋势,RIC可能更有利。
局限性
- 本研究为回顾性分析。
- 研究比较RIC与NMA预处理的文献有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic stem cell transplantation (HSCT) remains the only curative treatment for myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) patients. The introduction of reduced intensity (RIC) and non-myeloablative (NMA) conditioning enabled HSCT in older or comorbid individuals representing the majority of patients. Studies comparing RIC and NMA conditioning are limited. We retrospectively analyzed 151 MDS or MDS/MPN patients older than 50 years who received NMA- or RIC-HSCT. Patients younger or older than 65 years at HSCT were analyzed separately. Patients receiving RIC-HSCT or NMA-HSCT were balanced in factors reflecting disease aggressiveness and the HCT-CI comorbidity score. The NMA conditioned patients had a higher incidence of graft rejection and chronic graft-vs-host disease. Cumulative incidence of relapse (CIR), non-relapse mortality (NRM) and overall survival (OS), did not differ significantly with regard to the conditioning regime in the whole cohort. In patients <65 years at HSCT, NMA conditioning associated with higher NRM and shorter OS by trend, while CIR was similar in both groups. In multivariable analyzes, the conditioning regimen remained a prognostic factor for NRM and OS in patients <65 years at HSCT. In MDS patients NMA and RIC conditioning result in similar disease control, but especially patients <65 years may benefit from RIC-HSCT.
引用
- Jentzsch M, Döhring C, Linke R, et al. Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. Am J Hematol. 2019. PMID: 31495933. doi:10.1002/ajh.25636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。